Data Characteristics for this Category
Recombinant protein clinical trial pre-screening data primarily originates from biopharmaceutical companies' internal R&D databases, clinical trial reports from Contract Research Organizations (CROs), and public drug registration and clinical trial platforms. This data typically exists in structured formats (e.g., database records, CSV files) and semi-structured formats (e.g., PDF-formatted trial protocols, investigator brochures, patient medical records). Key data includes recombinant protein sequence information, expression vectors, purification processes, drug mechanisms of action, pharmacokinetic (PK) and pharmacodynamic (PD) data, preclinical toxicology reports, clinical trial inclusion/exclusion criteria, adverse event (AE) records, and efficacy endpoint data. Data update frequency depends on the clinical trial's progress, ranging from quarterly updates for early exploratory studies to monthly or even weekly updates for later-stage pivotal trials. Document structures are complex, often containing extensive specialized terminology and abbreviations. Fields and units strictly adhere to medical and pharmaceutical standards; for example, dose units are mg or μg/kg, time point units are hours, days, or weeks, and adverse event grade is typically 1-5.
Constraints Imposed by these Characteristics on "Deployment and Upgrades"
The complexity and specialized nature of recombinant protein data impose specific requirements on FastGPT's deployment and upgrade processes. First, the diversity of data sources necessitates robust multi-modal data ingestion and parsing capabilities, especially for PDF-formatted clinical trial documents, to ensure accurate extraction of tables, charts, and text. Second, frequent data updates require a flexible data synchronization mechanism capable of periodically pulling the latest data from various sources and performing incremental updates to ensure the timeliness of pre-screening results. The unique molecular structure and mechanism of action of recombinant proteins mean that vectorization and retrieval processes demand more refined semantic understanding to avoid information loss due to misinterpretation of specialized terms. For model selection, given the specialized nature of recombinant protein literature, deploying language models capable of handling long texts and possessing strong domain knowledge is crucial, along with ensuring their stable operation. Furthermore, the standardization of fields and units requires the system to maintain consistency during information extraction and result presentation to prevent misjudgments caused by unit confusion.
Configuration Guidelines
| Configuration Item | Suggested Value | Rationale |
|---|---|---|
maxContext | 16384 | Recombinant protein clinical trial documents are often long, requiring a larger context window to process complete information. |
PARSE_FILE_TIMEOUT_SECONDS | 600 seconds | Parsing large PDF documents is time-consuming; extending the timeout prevents parsing interruptions. |
Chunk size | 800–1200 characters | Ensures each segment contains sufficient professional context while avoiding excessive length that leads to information redundancy. |
Recall count | Top 10 entries | Clinical pre-screening requires comprehensive consideration of multiple relevant factors; increasing the number of recalled items improves coverage. |
Similarity threshold | 0.75 | The domain is highly specialized; increasing the similarity threshold ensures precise matching of recall results. |
Rerank result count | Top 5 entries | Based on highly accurate recall, re-ranking filters out the most relevant few results. |
Three Common Mistakes
- Encountering a
Connection refusederror when testing model links. This often indicates that the port of the locally deployed VLLM model is not correctly exposed or the IP address configured in FastGPT is incorrect. - Inability to extract response fields from the preceding PDF document parsing component. This typically occurs due to complex document structures or the model's
tokenencoding capability being insufficient to recognize key information in specific tables or charts. - New clinical trial data not reflecting in pre-screening results after data synchronization. This may be due to improper configuration of the incremental update strategy or the synchronization task not being adjusted in time after a data source change.
How to Verify Correct Configuration
- Upload a recombinant protein clinical trial PDF document containing complex tables and specialized terminology. Verify that its content is fully parsed and retrievable in the knowledge base via keyword search.
- Simulate a pre-screening query with specific inclusion/exclusion criteria. Check if the returned results accurately identify and cite detailed descriptions from relevant clinical trial protocols, paying close attention to the extraction of key fields like dose and time points.
- After deploying a new version of the language model, re-run a set of pre-screening queries with known results. Compare the performance of the new and old models in terms of specialized terminology understanding, long-text summarization, and reasoning capabilities to ensure no degradation in performance after the upgrade.
The values provided are common starting points and should be measured against the reader's own samples.
Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.